结局预指定需足够详细以防临床试验中的结局替换:一项案例研究
该研究基于TRIGGER集群随机试验数据,通过改变「再出血」结局的定义标准、评估方式和测量时间点进行再分析,评估不同结局定义对治疗效果估计的影响。结果显示不同定义下OR范围为0.23-0.94,P值范围<0.001-0.89,极端定义可导致从几乎无证据到极强证据的结论差异。结论强调结局预指定需足够详细以避免选择性报告最有利结果。
要点
- 结局定义不充分可导致OR从0.23到0.94、P值从<0.001到0.89的显著差异
- 不同结局定义可导致从几乎无治疗效果到极强治疗效果的结论反转
- 临床试验结局预指定应足够详细以避免选择性分析最有利结果
核心结论
- 结局预指定需足够详细,以避免不同定义被分析后仅报告最有利结果。
研究设计与样本
- 基于TRIGGER集群随机试验数据的再分析,比较两种红细胞输血策略对急性上消化道出血患者的效果。
- 通过改变再出血结局的定义标准、评估方式和测量时间点来评估不同定义对治疗效果估计的影响。
主要发现
- 不同结局定义下估计的OR范围为0.23-0.94,对应P值范围为<0.001-0.89。
- 一种定义显示几乎无治疗效果的证据(OR=0.94,95%CI=0.37-2.40,P=0.89)。
- 另一种定义显示极强的治疗效果证据(OR=0.23,95%CI=0.11-0.50,P<0.001)。
临床怎么用
- 临床试验设计时应足够详细地预指定结局定义,包括判定标准、评估方式和测量时间点。
- 分析时应严格遵循预指定结局定义,避免因定义不同而选择性报告最有利结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pre-specification of outcomes is an important tool to guard against outcome switching in clinical trials. However, if the outcome is not sufficiently clearly defined, then different definitions could be applied and analysed, with only the most favourable result reported. METHODS: In order to assess the impact that differing outcome definitions could have on treatment effect estimates, we re-analysed data from TRIGGER, a cluster randomised trial comparing two red blood cell transfusion strategies for patients with acute upper gastrointestinal bleeding. We varied several aspects of the definition of further bleeding: (1) the criteria for what constitutes a further bleeding episode; (2) how further bleeding is assessed; and (3) the time-point at which further bleeding is measured. RESULTS: There were marked discrepancies in the estimated odds ratios (OR) (range 0.23-0.94) and corresponding P values (range < 0.001-0.89) between different outcome definitions. At the extremes, differing outcome definitions led to markedly different conclusions; one definition led to very little evidence of a treatment effect (OR = 0.94, 95% confidence interval [CI] = 0.37-2.40, P = 0.89), while another led to very strong evidence of a treatment effect (OR = 0.23, 95% CI = 0.11-0.50, P < 0.001). CONCLUSIONS: Outcomes should be pre-specified in sufficient detail to avoid differing definitions being analysed and only the most favourable result being reported. TRIAL REGISTRATION: Clinical Trials.gov, NCT02105532 . Registered on 7 April 2014.
引用
- Kahan BC, Jairath V. Outcome pre-specification requires sufficient detail to guard against outcome switching in clinical trials: a case study. Trials. 2018. PMID: 29720248. doi:10.1186/s13063-018-2654-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。